Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector-Reference-Cited by-同舟云学术

Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector

Published:2013-03-18 Issue:3 Volume:9 Page:607-613
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Zuniga Amando,Liniger Mathias,Morin Teldja Neige Azzouz,Marty René R.,Wiegand Marian,Ilter Orhan,Weibel Sara,Billeter Martin A.,Knuchel Marlyse C.,Naim Hussein Y.

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/hv.23242

Reference35 articles.

1. An HIV Vaccine — Challenges and Prospects

2. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

3. Immunity to malaria: more questions than answers

4. Viral vector vaccines make memory T cells against malaria

5. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generation of recombinant measles virus containing the wild-type P gene to improve its oncolytic efficiency;Microbial Pathogenesis;2019-10

2. Measles-derived vaccines to prevent emerging viral diseases;Microbes and Infection;2018-10

3. Vaccine platform recombinant measles virus;Virus Genes;2017-07-14

4. Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines;Journal of General Virology;2016-09-01

5. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination;Human Vaccines & Immunotherapeutics;2015-12-02